BG-75202 is an orally bioavailable inhibitor of the histone acetyltransferases KAT6A (MOZ) and KAT6B (MORF), which binds these enzymes and inhibits acetylation of histones and other nonhistone substrates. It is studied in breast cancer and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.